COVID-19 — Recombinant Hyperimmune Polyclonal Antibody (GIGA-2050) in COVID-19 Patients
Citation(s)
A Phase 1 Single Ascending Dose Study of a Recombinant Hyperimmune Polyclonal Antibody Against SARS CoV-2 (GIGA-2050) in Patients Hospitalized With COVID-19